A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

NCT06397027 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Refractory Acute Leukemia
Pediatric Relapsed

Interventions

DRUG: Ziftomenib
DRUG: Venetoclax
DRUG: Azacitidine

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]